User menu

Effects of Clofibrate, Bezafibrate, Fenofibrate and Probucol On Plasma Lipolytic Enzymes in Normolipemic Subjects

Bibliographic reference Heller, F. ; Harvengt, C.. Effects of Clofibrate, Bezafibrate, Fenofibrate and Probucol On Plasma Lipolytic Enzymes in Normolipemic Subjects. In: European Journal of Clinical Pharmacology, Vol. 25, no. 1, p. 57-63 (1983)
Permanent URL http://hdl.handle.net/2078.1/56589
  1. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 302: 1219?1222
  2. Huy DY, Innerarity TL, Wahley RW (1981) Lipoprotein binding to canine hepatic membranes. J Biol Chem 256: 5646?5655
  3. Glomset JA (1968) The plasma lecithin: Cholesterol acyltransferase reduction. J Lipid Res 9: 155?167
  4. Tall AR, Small DM (1978) Plasma high-density lipoproteins. N Engl J Med 299: 1232?1236
  5. Greten H, Laible V, Zipperle G, Augustin J (1977) Comparison of assay methods for selective measurement of plasma lipase. Atherosclerosis 26: 563?572
  6. Boberg J, Boberg M, Gross R, Grundy S, Augustin J, Brown V (1977) The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post heparin plasma in male patients with hyperlipoproteinemia. Atherosclerosis 27: 499?503
  7. Nikkil� EA, Huttunen JK, Ehnholm C (1977) Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 26: 179?186
  8. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkil� EA (1979) Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073?1076
  9. Wallentin L (1978) Lecithin: Cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and clofibrate treatment of hypertriglyceridemic subjects. Atherosclerosis 31: 41?52
  10. Pignard P (1980) Le probucol. Propri�t�s physico-chimiques et m�thodes de dosage. Nouv Presse Med 9: 2973?2975
  11. Lopes-Virella MF, Stone M, Ellis S, Colwell JA (1977) Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 23: 882?884
  12. Friedwald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499?502
  13. Stokke KT, Norum KR (1971) Determination of lecithin: Cholesterol acyltransfer in human blood plasma. Scand J Clin Lab Invest 27: 21?27
  14. Heller F, Desager JP (1978) Plasma lecithin: Cholesterol acyltransferase: Lack of induction by phenobarbital in humans. Artery 4: 231?238
  15. Nilsson-Ehle P, Ekman R (1977) Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery 3: 194?209
  16. Harvengt C, Desager JP (1977) Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol 15: 1?4
  17. Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene a new hypolipidemic drug in volunteers. Int J Clin Pharmacol Biopharm 16: 570?574
  18. Abshagen U, Bablok W, Koch K, Lang PD, Schmidt HAE, Senn M, Stork H (1979) Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 16: 31?38
  19. Meloy D, Caldwell WJ (1978) Analysis and validation of DH-581 in plasma using HPLC-UV. Report NBL 166 of the Dow Chemical Company, USA
  20. Harvengt C, Heller F, Desager JP (1980) Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 7: 73?82
  21. Olsson AG, R�ssner S, Walldius G, Carlson LA, Lang PD (1977) Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 27: 279?287
  22. Heller F, Desager JP, Harvengt C (1981) Plasma lipid concentrations and lecithin: Cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 30: 67?71
  23. Riesen WF, Keller M, Mordasini R (1980) Probucol in hypercholesterolemia. A double blind study. Atherosclerosis 36: 201?207
  24. Hunninghake DB, Bell C, Olson L (1980) Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. Atherosclerosis 27: 469?474
  25. Mellies MJ, Gartside PS, Glatfelter L, Vink P, Guy G, Schonfeld G, Glueck JC (1980) Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Metabolism 29: 956?964
  26. McCaughan D (1982) Nine years of treatment with probucol. Artery 10: 56?70
  27. Heeg JF, Tachizawa H (1980) Taux plasmatiques du probucol chez l'homme apr�s administration orale unique ou r�p�t�e. Nouv Presse Med 9: 2990?2994
  28. Taylor KG, Holdsworth G, Galton DJ (1977) Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients. Lancet 2: 1106?1107
  29. Lithell H, Boberg J, Hellsing K, Lundqvist G, Vessby B (1978) Increase of the lipoprotein-lipase activity in human skeletal muscle during clofibrate administration. Eur J Clin Invest 8: 67?74
  30. D'Costa MA, Smigura FC, Kulhay K, Angel A (1977) Effects of clofibrate on lipid synthesis, storage, and plasma intralipid clearance. J Lab Clin Med 90: 823?836
  31. Vessby B, Lithell H, Hellsing K et al. (1980) Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis 37: 257?259
  32. Vessby B, Lithell H, Lederman H (1982) Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. Atherosclerosis 44: 113?118
  33. Klose G, Behrendt J, Vollmar J, Greten H (1980) Effect of bezafibrate on the activity of lipoprotein lipase and hepatic triglyceride hydrolase in healthy volunteers. In: Greten H, Lang PD, Schettler G (eds) Lipoproteins and coronary heart disease ? New aspects in the diagnosis and therapy of disorders of Lipid Metabolism. Gerhard Witzstrock, Baden-Baden, FRG, p 182
  34. Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1981) Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase. Clin Chim Acta 113: 59?64
  35. Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1982) Clinical experience with probucol with special emphasis on mode of action and long-term treatment. Artery 10: 35?43.
  36. Nestel PJ, Billington T (1981) Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38: 203?209
  37. Simons LA, Balasubramaniam S, Beins DM (1981) Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis 40: 299?308